<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FEC5FE7D-C329-4D18-9A3A-FAC03968DF93"><gtr:id>FEC5FE7D-C329-4D18-9A3A-FAC03968DF93</gtr:id><gtr:name>San Francisco University</gtr:name><gtr:address><gtr:line1>2130 Fulton Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:department>Transplantation Immunology &amp; Mucosal Bio</gtr:department><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FEC5FE7D-C329-4D18-9A3A-FAC03968DF93"><gtr:id>FEC5FE7D-C329-4D18-9A3A-FAC03968DF93</gtr:id><gtr:name>San Francisco University</gtr:name><gtr:address><gtr:line1>2130 Fulton Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37D03EDF-A585-4D7B-8E46-7A48F11DA5DC"><gtr:id>37D03EDF-A585-4D7B-8E46-7A48F11DA5DC</gtr:id><gtr:name>University Hospital Regensburg</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/75BE9D63-F23B-4C55-A53C-ED9D475667BC"><gtr:id>75BE9D63-F23B-4C55-A53C-ED9D475667BC</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:surname>Heaton</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/303E9ED2-5A13-4CC2-90BD-034FF298566D"><gtr:id>303E9ED2-5A13-4CC2-90BD-034FF298566D</gtr:id><gtr:firstName>Irene</gtr:firstName><gtr:surname>Rebollo Mesa</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/665E3D2C-C21E-44A7-A346-AB2C948142F9"><gtr:id>665E3D2C-C21E-44A7-A346-AB2C948142F9</gtr:id><gtr:firstName>Niloufar</gtr:firstName><gtr:surname>Safinia</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/C10DF287-D67D-464B-A6D8-71BE09AAD280"><gtr:id>C10DF287-D67D-464B-A6D8-71BE09AAD280</gtr:id><gtr:firstName>Varuna</gtr:firstName><gtr:surname>Aluvihare</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/D755320B-897A-4664-984C-1480D6978A96"><gtr:id>D755320B-897A-4664-984C-1480D6978A96</gtr:id><gtr:firstName>Robert</gtr:firstName><gtr:surname>Lechler</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/BC964C6C-F79A-41B6-A1EF-5AA226783D57"><gtr:id>BC964C6C-F79A-41B6-A1EF-5AA226783D57</gtr:id><gtr:firstName>Janet</gtr:firstName><gtr:otherNames>Lesley</gtr:otherNames><gtr:surname>Peacock</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB4046D3-FCA3-4BF4-90CA-1FA857B89F32"><gtr:id>FB4046D3-FCA3-4BF4-90CA-1FA857B89F32</gtr:id><gtr:firstName>Giovanna</gtr:firstName><gtr:surname>Lombardi</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/8AE46C95-7B32-4581-8567-6859F1B2E1AB"><gtr:id>8AE46C95-7B32-4581-8567-6859F1B2E1AB</gtr:id><gtr:firstName>Alberto</gtr:firstName><gtr:surname>Sanchez-Fueyo</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK025538%2F1"><gtr:id>4EF6BA2D-202C-40FB-B905-5CE4A847515E</gtr:id><gtr:title>ThRIL;A 'first-in-human' study, evaluating the safety, tolerability with an investigation into the efficacy of Tregs in liver transplant recipients</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K025538/1</gtr:grantReference><gtr:abstractText>Liver transplantation is a successful treatment for patients with severe liver disease. Despite this, the majority of patients are maintained on immunosuppressants (drugs that dampen down the immune system) life long with associated side effects, affecting the quality of life of the patient and the long term outcome. The aims of this study are, therefore, to i. determine if a new cell based therapy is safe and well tolerated in liver transplantation patients and ii. if immunosuppressive drugs can be withdrawn early after transplantation (once the patient has had this new therapy).
The general aim of this therapy is to allow the withdrawal of immunosuppressants in patients receiving a liver transplant, with the ultimate goal of complete withdrawal of immunosuppressants lifelong.

Interestingly, populations of immune cells in the recipient, called regulatory T cells, have been shown to regulate the patient's immune system and prevent against organ rejection. Our research is targeting at developing new treatments that involve increasing the number of these cells in the recipient. We will a. isolate these cells from the recipient at the time of transplant, expand them numerically and ensure they are stable in culture and then inject them back into the patient at 3 months after transplantation. Patients will be closely monitored at King's College Hospital (expertese in hepatology and liver transplantation) with assessment of safety of the injected cells.

The study's main focus is the assessment of safety of the cell based therapy and providing evidence which will support a larger study looking at the effectiveness of the therapy in the liver transplant recipients.</gtr:abstractText><gtr:technicalSummary>Liver transplantation(LT) is a successful treatment for end-stage liver disease. Despite this long-term survival remains suboptimal because of the morbidity and mortality associated with long-term use of immunosuppression(IS). However IS weaning early post LT has been largely unsuccessful, supporting the need for active tolerance induction strategies.

CD4+CD25+FOXP3+cells(Tregs) play an important role in immunoregulation. We have shown that in vitro expanded murine and human Tregs promotes transplantation tolerance in animal models. The safety of these cells has been already demonstrated in phase I trials of bone marrow transplantation. ThRIL will be the first combined phase I/II clinical trial of Treg therapy in solid organ transplantation.

The protocol we have devised involves the isolation and expansion of Tregs, harvested at time of transplantation from blood of LT recipients. We have expertise in expansion of large numbers of functionally suppressive and stable Tregs from healthy controls at GMP standard. We have obtained similar results using blood from LT recipients.

ThRIL is an open label, randomised, controlled, parallel group, single ascending dose study, investigating the safety and tolerability of Treg immunotherapy with a cohort expansion to investigate for a signal of efficacy. Patients will be treated with ATG at time of transplantation, and started on Tacrolimus. Rapamycin will be started at 2 months, with an infusion of Tregs at 3 months post transplantation. Two dose levels of Tregs will be assessed, a low (1.0x10^6cells/kg) and high (4.5x10^6cells/kg) dose (3 active:1 control). The chosen doses are comparable to what has been safely used in published clinical trials (3x10^6cells/kg). The cohort of patients receiving the dose which is safe and well tolerated will be expanded to investigate an efficacy signal, providing the evidence required to take the development of Treg immunotherapy towards a larger Phase II/III study.</gtr:technicalSummary><gtr:potentialImpactText>In accordance to ethical principals as set out in the World Medical Association Declaration of Helsinki, the participants in this study are from a population of patients who stand to benefit from the results of the research.

Treg immunotherapy has the potential to be of great benefit to patients with liver transplantation, as this would allow the reduction, if not cessation, of immuno-suppressive therapy that has numerous side effects and their consequent morbidities.

This study will provide the safety, tolerability and some efficacy information for Treg immunotherapy in patients who have had a liver transplantation. In particular liver transplantation patients whose MELD score at transplantation is less than 25 at the time of transplantation (excluding patients with HCV, autoimmune liver disease). The majority of these patients will be undergoing liver transplantation for cirrhosis secondary to alcohol and/or for HCC in the setting of Hepatitis B, alcoholic or cryptogenic cirrhosis.

If it is shown to be safe and well tolerated this would allow the progression to trials that investigate efficacy of Treg immunotherapy and potentially lead to a new modality of treatment for these patients, which has less side effects than conventional immuno-suppressive therapy.

If Treg immunotherapy is able to generate tolerance in the setting of liver transplantation, the solution will not only benefit the patients, that will receive the Treg immunotherapy, but also those not suitable for nTreg immunotherapy but on the transplant waiting list. If Treg therapy is successful at inducing indefinite graft survival, immunosuppression can be withdrawn from patients receiving the therapy and patients ill no longer suffer the associated side effects of the immuno-suppressive regimen. Furthermore, this will also lead to less re-transplant and more organ available to be used for other patients on the transplant waiting list.

Furthermore if Treg immunotherapy is found to be efficacious in liver transplantation patients, this would be an indication that it might be of use in other solid organ transplantation, such as kidney. Therefore providing indirect evidence of a potential new modality of treatment in other solid organ transplantation.

Moreover this study will have a substantive impact in the field of transplantation, if successful it will pave the way towards a larger combined Phase II/III study and will inform other tolerance inducing protocols. However if unsuccessful it will be informative in aiding the design of future tolerance inducing strategies.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-02-17</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-08-31</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>2042677</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of San Francisco (USF)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Cell therapy in liver transplant patients</gtr:description><gtr:id>687E34F4-C0D9-4DD5-9B77-3CA7393FC02D</gtr:id><gtr:impact>1 publication so far.</gtr:impact><gtr:outcomeId>Wb6BSDfqv1t-1</gtr:outcomeId><gtr:partnerContribution>Generation of antigen-specific Tregs using B cells as antigen presenting cells.</gtr:partnerContribution><gtr:piContribution>Comparison of cell therapy using two preparations of regulatory T cells in liver transplant patients with the same clinical therapy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University Hospital Regensburg</gtr:collaboratingOrganisation><gtr:country>Germany, Federal Republic of</gtr:country><gtr:description>EU Consortium</gtr:description><gtr:id>2C3B4444-18F1-44A0-8A8B-002D63DB2357</gtr:id><gtr:impact>Few manuscripts submitted.</gtr:impact><gtr:outcomeId>TtbvTEQ5mQe-2</gtr:outcomeId><gtr:partnerContribution>Use of different cell type with the aim to induce tolerance in renal transplant patients</gtr:partnerContribution><gtr:piContribution>Use of regulatory Tregs for the induction of tolerance in renal transplant patients</gtr:piContribution><gtr:sector>Hospitals</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Key note speaker at conference- CST-CNTRP-SQT Joint scientific Meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>195E1063-057C-4ECA-A52F-AF14C0E5DB2D</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;The use of Tregs in Kidney Transplantation.&amp;quot;</gtr:impact><gtr:outcomeId>58b590d2c75879.07597781</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker at a conference- 3rd International Molecular and Immunology &amp; Immunogenetics Congress</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2FE0705C-F3B4-43CF-94B1-01C4094FCB86</gtr:id><gtr:impact>Talk entitled: &amp;quot;Clinical grade manufacture of Regulatory T cells to promote Transplantation Tolerance: Challenges and Achievements.&amp;quot;</gtr:impact><gtr:outcomeId>58b58e40ac7075.22974876</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016,2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker- Inaugural UK Regenerative Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>B0B5B1C7-E455-4A32-A94E-FF5E51FC1ACE</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot; Immunological characterisation of IPS-derived cells.&amp;quot;</gtr:impact><gtr:outcomeId>58b58ff4727bb4.37533680</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Co-organiser and chair person at Humanised Mouse Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>84E60392-90C3-4C06-BCFF-1FE3CFA38E66</gtr:id><gtr:impact>Co-organised and chaired a workshop humanised mouse symposium</gtr:impact><gtr:outcomeId>58c2d027776281.41210299</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Personally asked as a key note speaker to a conference- AFACRR Management Committee and working group- Belgrade</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D65FC702-8190-4543-BC74-FC63B08F93AF</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;Clinical grade manufacture of Regulatory T Cells to promote Transplantation Tolerance: Challenges and Achievements.&amp;quot;</gtr:impact><gtr:outcomeId>58b58ef5d4e468.67590100</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Committee Member- ONE Study, Regensberg</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E63AE388-CC0F-4A1C-8E4B-915AAF77230B</gtr:id><gtr:impact>Participant to discussions as a member of the committee and working group</gtr:impact><gtr:outcomeId>58b5911d7d37e6.80632122</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Member of committee- TWO Study meeting</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FB2692F1-3951-45ED-BAE0-60BB6DC8931D</gtr:id><gtr:impact>participant of committee and to discussions at this meeting</gtr:impact><gtr:outcomeId>58b591e5823725.38678282</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Key note speaker to conference- Club de la Transplantation- Lille, France</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>98589266-CA57-4D0D-B21E-0322BB16D481</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;Immunotherapy after TH, ThRIL Trial</gtr:impact><gtr:outcomeId>58b59195e52e09.44254586</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ELRIG Research and Innovation conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F317AC6C-9EAE-4BE5-B4B0-2F0365DDC1F0</gtr:id><gtr:impact>Regulatory T cell therapy in organ transplantation</gtr:impact><gtr:outcomeId>58c2d0979198d2.69395638</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Science Museum</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>001DE833-F733-4A9C-9E7B-0C616F60DFE5</gtr:id><gtr:impact>MRC-funded event at London's Science Museum to mark the Medical Research Council's Centenary, showcasing the work of 9 London MRC Centres including the research taking place in the Immunoregulation Laboratory. A total of 1,332 visitors attended the festival over the weekend. Visitors discovered what happens after a transplant and learnt about our research, which aims to help patients return to a healthy life. This was summarized into one key message: &amp;quot;We can improve long term quality of life for transplant patients by using their own cells to aid recovery instead of drugs&amp;quot;.


A total of 1,332 visitors attended the festival over the weekend.</gtr:impact><gtr:outcomeId>HUxmZ2vn4Ym</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.sciencemuseum.org.uk/about_us/press_and_media/press_releases/2013/06/Life%20Game.aspx</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NIHR in BTRU in ODT</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AD021FAD-224F-476D-BE24-FF8D365C5576</gtr:id><gtr:impact>interactive workshop involving academics creating a forum to present and share ideas</gtr:impact><gtr:outcomeId>58c2d13768af86.00605240</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Visit of MEP and MP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E155CC51-64AA-48A9-A52F-55169CF70D1D</gtr:id><gtr:impact>One MEP and one MP attended to receive information about the involvement of King's in EU funding scheme.

They will report the success of Kings in gaining EU funding at parliamentary and european levels.</gtr:impact><gtr:outcomeId>C1y8B2oGWsK</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Policymakers/parliamentarians</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>key note speaker to conference- Instituo de Medicina Molecular- Lisbon</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C854441A-20D3-4ADF-83C1-19C7042CDBE2</gtr:id><gtr:impact>Gave a talk entitled: &amp;quot;Approaching clinical Transplantation tolerance.&amp;quot;</gtr:impact><gtr:outcomeId>58b5926037a424.83087103</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Committee Chair Member- Cost, Galway</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>EB48FEA3-0276-4A28-A5C0-CBA3E40A9E7C</gtr:id><gtr:impact>Chair person and participant to discussions at COST, Galway meeting</gtr:impact><gtr:outcomeId>58b5907d4da571.91069489</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>Cell therapy in liver transplant patients. Cell product in development in the GMP facility. Financed by the MRC.</gtr:description><gtr:id>59B69A2A-F961-4018-8F8B-358B64A98C1D</gtr:id><gtr:impact>Immunosuppressive withdraw in liver transplant patients and indefinite survival of the transplant.</gtr:impact><gtr:outcomeId>cT3KT8Unrtp</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>ThRIL-liver transplant patients</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Completed the pre-clinical assessment of the product in the GMP facility. Financed by the EU.</gtr:description><gtr:id>50DAF783-EDAD-4473-AED8-328F108D3606</gtr:id><gtr:impact>So far in vitro the first patient will be treated with this cell product in February 2014.</gtr:impact><gtr:outcomeId>DRxcZx8KFpj</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>The One Study-renal transplant patient</gtr:title><gtr:type>Therapeutic Intervention - Cellular and gene therapies</gtr:type><gtr:yearDevCompleted>2013</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Immunodeficient mice reconstituted with human blood to study human immune responses in vivo and develop strategies to interfere with them.</gtr:description><gtr:id>CF627482-FDB1-4518-A247-533454E284FB</gtr:id><gtr:impact>Publications and future collaborations.</gtr:impact><gtr:outcomeId>szwbENVH7Fd</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Humanised mouse model</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>0F353A38-3835-4704-9DD7-31E98F47F7F5</gtr:id><gtr:title>Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4(+)CD25(+)FOXP3(+) T regulatory cell subpopulations.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a501a6a9751751d9907ecb97f8214a5f"><gtr:id>a501a6a9751751d9907ecb97f8214a5f</gtr:id><gtr:otherNames>Scott? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>pm_14815_25_23242600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D3F5A14D-8DA1-4A6F-8EF8-CD384DFCDBE3</gtr:id><gtr:title>Treg therapy in transplantation: a general overview.</gtr:title><gtr:parentPublicationTitle>Transplant international : official journal of the European Society for Organ Transplantation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/32ae8244d7b23002c2b8fee8ecc0bf07"><gtr:id>32ae8244d7b23002c2b8fee8ecc0bf07</gtr:id><gtr:otherNames>Romano M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0934-0874</gtr:issn><gtr:outcomeId>58b58b3dd1a6a9.28001539</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5A6FDC5-4175-43D9-80C8-199F72DFBA00</gtr:id><gtr:title>Assessment of regulatory T-cell function in forthcoming clinical trials of cell therapy.</gtr:title><gtr:parentPublicationTitle>Expert review of molecular diagnostics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1473-7159</gtr:issn><gtr:outcomeId>pm_14815_25_23256698</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0EB0124F-93C0-4B14-9E5C-4573954C020C</gtr:id><gtr:title>Phenotypic Complexity of the Human Regulatory T Cell Compartment Revealed by Mass Cytometry.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/be4eba9249e5210879c5ba825b58c879"><gtr:id>be4eba9249e5210879c5ba825b58c879</gtr:id><gtr:otherNames>Mason GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56cdd09f5f7a55.43511183</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A899B6AA-6E61-4457-87A2-581415DB204A</gtr:id><gtr:title>CD161 expression characterizes a subpopulation of human regulatory T cells that produces IL-17 in a STAT3-dependent manner.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>pm_14815_25_23677517</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3467C5D5-31FC-4348-9916-5E579C8056BF</gtr:id><gtr:title>Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation.</gtr:title><gtr:parentPublicationTitle>American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2bb453a9737fc82f8737f2fba61ff2cc"><gtr:id>2bb453a9737fc82f8737f2fba61ff2cc</gtr:id><gtr:otherNames>Putnam AL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1600-6135</gtr:issn><gtr:outcomeId>543b98d787c351.72963403</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>163151D7-E8DF-4986-8F6D-E16FE4A762BA</gtr:id><gtr:title>Promoting transplantation tolerance; adoptive regulatory T cell therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>pm_14815_25_23574313</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E2C2F776-C588-464F-9E4B-5ABC8C60AAE7</gtr:id><gtr:title>Successful expansion of functional and stable regulatory T cells for immunotherapy in liver transplantation.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f79b3b082d0af0f2cd8470d59b7efb"><gtr:id>f8f79b3b082d0af0f2cd8470d59b7efb</gtr:id><gtr:otherNames>Safinia N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>56cdd3d36391d9.75063874</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>63D52CDD-A94A-434E-A9E4-D57453D2F912</gtr:id><gtr:title>Impact of immunosuppressive drugs on the therapeutic efficacy of ex vivo expanded human regulatory T cells.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a501a6a9751751d9907ecb97f8214a5f"><gtr:id>a501a6a9751751d9907ecb97f8214a5f</gtr:id><gtr:otherNames>Scott? C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>56cdd1e53f5042.79215164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3FC1B17-C6E1-4C68-AA5E-6A8CF8310235</gtr:id><gtr:title>Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/106c16d6f9893f7a7d87dd13518ba4f7"><gtr:id>106c16d6f9893f7a7d87dd13518ba4f7</gtr:id><gtr:otherNames>Canavan JB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56cdd09ef26165.92226027</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF3B56B4-246A-4DF3-9960-18B5E89F4E6D</gtr:id><gtr:title>Comparison of regulatory T cells in hemodialysis patients and healthy controls: implications for cell therapy in transplantation.</gtr:title><gtr:parentPublicationTitle>Clinical journal of the American Society of Nephrology : CJASN</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a24f02668e536a6d0df0cd985e178d88"><gtr:id>a24f02668e536a6d0df0cd985e178d88</gtr:id><gtr:otherNames>Afzali B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1555-9041</gtr:issn><gtr:outcomeId>pm_14815_25_23580782</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K025538/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>0CDFB83C-594C-4860-B0BE-C82CA4D45B6B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.2  Cellular and gene therapies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>046212FE-8853-46F0-B1E7-3CBA4770A15F</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.4  Surgery</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>